Breaking Canadian GLP-1 news
GLP-1 News — Page 11
Drug approvals, price changes, generic timelines, and clinical trial results affecting GLP-1 medication costs in Canada.
Find my best option
Answer a few quick questions — get your cheapest path to a GLP-1 prescription, free.
Vimy Pharma to File Generic Semaglutide Application to Health Canada
Canadian pharmaceutical company Vimy Pharma expects to submit its generic semaglutide application to Health Canada within weeks. - GLP1Prices.ca
Health Canada Approves First GLP-1 Daily Pill Rybelsus 2026
Health Canada has approved Rybelsus as the first daily oral GLP-1 medication, marking a regulatory milestone. Compare prices at GLP1Prices.ca
Aspen Pharmacare Targets September 2026 for Generic Ozempic Launch
South African drugmaker expects Health Canada approval by Q3 2026 for generic semaglutide. Latest updates at GLP1Prices.ca
Study: Semaglutide Could Be Made for $3 Monthly in Canada
New study reveals semaglutide manufacturing costs just $3 monthly, highlighting potential for dramatic price reductions - GLP1Prices.ca
Canada Becomes Global Launching Pad for Generic Ozempic Race
With semaglutide patents expired, Canada emerges as the world's first major market for generic Ozempic competition. Compare prices at GLP1Prices.ca
Health Canada Reviews 9 Generic Semaglutide Applications for 2026
Health Canada is reviewing nine generic semaglutide applications with approvals expected Q3 2026, potentially making Canada first market for cheaper alternatives. GLP1Prices.ca
Novo Nordisk to Cut Ozempic, Wegovy Prices Up to 50% in 2027
Danish drugmaker announces major price reductions for GLP-1 medications facing generic competition. Compare current Canadian prices at GLP1Prices.ca
Health Canada Warns of Fake Ozempic and Mounjaro Sales in Canada 2026
Health Canada identifies retailers selling unauthorized GLP-1 drugs using fake logos and endorsements. Safety alert issued January 21, 2026. GLP1Prices.ca
3 Million Canadians Use GLP-1 Drugs as Generic Competition Looms
New survey reveals 3 million Canadian adults currently take GLP-1 medications like Ozempic and Mounjaro, with cost barriers limiting wider adoption. GLP1Prices.ca
GLP-1 Medications Straining Canadian Employer Drug Plans in 2026, Report Finds
Alberta Blue Cross's 2026 drug pipeline report reveals GLP-1 medications are creating enormous cost pressure on Canadian employer benefit plans, with Wegovy at ~$5,000/year and generic semaglutide unlikely to fully offset surging utilization.
BC Launches National Pharmacare on March 1, 2026: What It Means for Drug Coverage
British Columbia becomes the first province to implement national pharmacare, covering diabetes drugs and contraceptives for over 500,000 residents — but GLP-1 medications like Ozempic are not yet included.
Novo Nordisk Warns of Sales Decline as Generic Semaglutide Threatens Canadian Market
Novo Nordisk forecasts 5–13% sales decline in 2026 as semaglutide exclusivity expires. Generic pricing could drop 35–70% below branded Ozempic in Canada.
Novo Nordisk’s CagriSema Falls Short Against Zepbound in Head-to-Head Trial
REDEFINE 4 trial results show CagriSema achieved 23% weight loss vs tirzepatide’s 25.5% after 84 weeks. Novo Nordisk shares dropped 13–16% on the news.
Generic Ozempic Delayed: Health Canada Backlog Pushes Timeline to Q3 2026
Nine generic semaglutide submissions face Health Canada review delays. Dr. Reddy’s received a rejection; Sandoz now targets Q3 2026 for generic Ozempic launch.
Looking for current pharmacy prices?
Compare GLP-1 prices across Canada